SCHEMBL3928463

SCHEMBL3928463

CCCCN(Cc1ccccc1)C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
HDAC6 Q9UBN7 4/20 0.55
HDAC1 Q13547 3/20 0.55
PKM P14618 2/20 0.54
LMNA P02545 1/20 0.53
CNR2 P34972 1/20 0.52
LTB4R2 Q9NPC1 3/20 0.52
LIMK1 P53667 1/20 0.52
LIMK2 P53671 1/20 0.52
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
HDAC3 O15379 2/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC4 P56524 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3418990 0.94 CNR2 (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3920435 0.90 LMNA (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Decane SCHEMBL9298496 0.88 LMNA (0.54) PKMLMNACNR2LTB4R2
Hexadecane SCHEMBL9298501 0.88 LMNA (0.54) PKMLMNACNR2LTB4R2
SCHEMBL1753870 0.88 HDAC6 (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11050378 0.85 HDAC6 (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3900020 0.85 HDAC1 (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2187349 0.85 HDAC6 (0.56) HDAC6HDAC1PKMLMNACNR2
SCHEMBL8805242 0.83 GRIN2D (0.77) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL28884103 0.83 HDAC1 (0.74) HDAC6HDAC1PKMLTB4R2LIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 US disclosed
US-10336711-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2019-07-02 US disclosed
US-20180305323-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2018-10-25 US disclosed
US-20150315157-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-11-05 US disclosed
US-20140336383-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-11-13 US disclosed
US-8557834-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-03-21 US disclosed
CN-101289355-B Herbicide-fertilizer composite granule for paddy rice, preparation and use method thereof BEIJING YIKEMAN BIOLOG TECHNOLOGY CO LTD 2011-05-04 CN disclosed
EP-2037922-A2 PROLYL HYDROXYLASE INHIBITORS SmithKline Beecham Corporation (US) 2009-03-25 EP disclosed
CN-101289355-A Herbicide-fertilizer composite granule for paddy rice, preparation and use method thereof BEIJING YIKEMAN BIOLOG TECHNOL (CN) 2008-10-22 CN disclosed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 WO disclosed
US-4397868-A INHIBITORS OF FATTY ACYL CHOLESTEROL ACYL TRANSFERASE AMERICAN CYANAMID COMPANY (US) 1983-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-10336711-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-20140336383-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-20180305323-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885
US-20150315157-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 GRIN2D 3898/4885GRIN3B 3401/4885GRIN1 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.